Loading
Life sciences · Journal article
Biomedicines · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: The relationship between low-grade inflammation and anti-Müllerian hormone (AMH) in Polyendocrine Metabolic Ovarian Syndrome (PMOS) remains incompletely understood. This study aimed to compare inflammatory markers and AMH concentrations between non-obese women with PMOS and controls and to assess the associations between these markers and AMH. Methods: This single-centered retrospective study involved 92 patients divided into two groups: a control group of 45 patients and 47 patients newly diagnosed with PMOS according to Rotterdam criteria. Results: Compared with controls, patients with PMOS had significantly higher median concentrations of CRP (3.902 vs. 1.038), IL-6 (4.15 vs. 2.28), and TNF-α (3.35 vs. 1.95), as well as higher white blood cell and lymphocyte counts. Median AMH (6.47 vs. 3.04), LH (8.77 vs. 6.93), and testosterone (0.415 vs. 0.317) concentrations were also significantly higher in the PMOS group. Conversely, NLR and PLR were higher in controls. When both groups were analyzed together, AMH correlated positively with IL-6 (r = 0.53), CRP (r = 0.53), TNF-α (r = 0.54), LH (r = 0.50), and testosterone (r = 0.44). In the pooled cohort, AMH correlated positively with CRP, IL-6, and TNF-α. Although TNF-α was significantly associated with AMH in the initial multivariable quantile regression models, these associations were no longer statistically significant after adjustment for PCOS/control status. Group status remained significantly associated with AMH at the 90th percentile. Conclusions: No statistically significant correlations were found between AMH levels and inflammatory markers in non-obese patients with PMOS or in healthy women.